Abbott licenses ALZpath pTau217 antibody for Alinity blood-based Alzheimer’s test development

Abbott Laboratories

Abbott Laboratories

ABT

0.00
  • Abbott signed a global licensing agreement with ALZpath to use ALZpath’s proprietary pTau217 antibody in an Alzheimer’s blood-based IVD test.
  • The assay is being developed for Abbott’s Alinity ci-series systems, targeting broad deployment across one of the largest immunoassay install bases.
  • ALZpath’s pTau217 antibody has clinical validation support from more than 200 peer-reviewed studies across 18 countries.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606240830PR_NEWS_USPR_____IO91108) on June 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.